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prostate adenocarcinoma predisposition
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Abstract
Background: Prostate cancer is one of the five common cancers and has the second incidence rate and the third
mortality rate in Iranian population. The purpose of this study was to evaluate the association of rs16901979, rs4242382
and rs1447295 on 8q24 locus, rs2735839 (KLK3 gene) and rs721048 (EHBP1 gene) with prostate adenocarcinoma
through multi-stage approach to identify the polymorphisms associated with prostate cancer and use them as
screening factors. Screening tests can identify people who may have a chance of developing the disease before
detection and any symptoms.
Methods: The case-control study included 103 cases (prostate adenocarcinoma) and 100 controls (benign prostatic
hyperplasia). Tetra-primer ARMS-PCR was used to genotyping of each participant. A Multi-stage approach was used for
efficient genomic study. In this method, a smaller number of people can be used. Chi-squared, Fisher’s exact test and
logistic regression were used to investigate the SNPs associated with prostate cancer and Gleason score.
Results: In the first stage (59 men), the frequency of polymorphisms rs16901979, rs4242382, rs1447295, rs2735839 and
rs721048 in the prostate adenocarcinoma group was evaluated compared to the control group (P-value < 0.3) in order
to select meaningful polymorphisms. There was not any significant difference between genotype frequency
rs16901979 (P = 0.671) and rs721048 (P = 0.474) in the case group compared to BPH. Therefore, these
polymorphisms were eliminated, and in the second step (144 men), rs4242382, rs2735839 and rs1447295 were
evaluated (P-value < 0.05). According to the total population (203 men), there was significant difference between
genotype frequency rs4242382 (P = 0.001), rs2735839 (P = 0.000) and rs1447295 (P = 0.005) even after using Bonferroni
correction (p = 0.016). The effect of these three polymorphisms on prostate cancer was not modified by age and PSA.
There was a significant difference between the allelic frequency of A vs G (rs4242382, rs2735839) at all classes of
Gleason score and A vs C (rs1447295) at Gleason score≥ 8.
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Conclusions: The results of this study for rs2735839, rs4242382 and rs1447295 indicate the association of these
polymorphisms with prostate adenocarcinoma predisposition in Iranian population. Exposure effect is homogeneous
between different ages and PSA level categories. These three polymorphisms should be studied in a larger population
to confirm these results.
Keywords: Benign prostatic hyperplasia (BPH), PSA, 8q24, EHBP1, Single nucleotide polymorphism (SNP), KLK3
Background
Prostate cancer is a malignancy, which in most cases is
prostatic adenocarcinoma amongst men, in which tumor
cells begin to grow and proliferation of the epithelial tissue
[1–4]. About 70% of the prostate tumors originate from
the peripheral zone, 25% from the Transition zone and 5%
from the central zone [5–8]. The incidence of this cancer
varies among different populations. The highest and the
lowest prevalence have been found in the African-
American and South Asian races respectively [9, 10]. Des-
pite the trend toward declining in the incidence and mor-
tality rates of prostate cancer in the United States and
some other Western countries, the incidence of this can-
cer is increasing in less developed and developing country
[9–12]. In Iran, the prevalence as with other developing
countries, is increasing [13]. According to recent GLOBO-
CAN reports in 2018, Age-Standardized Incidence Rate
(ASIR) and Age-Standardized Mortality Rate (ASMR) of
prostate cancer were 16.6 and 8.3 per 100,000 populations
in Iran. Therefore, it has the second incidence rate and
the third mortality rate [13].
In the early stages of the cancer, when the tumor is
limited to the prostate tissue itself, its symptoms are
rare. But the main symptoms that arise when the cancer
progresses include frequent urination, urinary incontin-
ence, hematuria (blood in the urine), persistent pain in
the lower back or pelvic cavity. Early diagnosis and ac-
curate classification of prostate cancer are vital because
survival rate is much reduced when the cancer spreads
beyond the prostate. Because of tissue heterogeneity in
prostate cancer, there is no specific imaging for the early
diagnosis. Hence, the first step in diagnosis is usually the
Prostate specific antigen (PSA) test and digital rectal
exam (DRE) [2–4]. The PSA test, although is dedicated
to the prostate gland, it is not proprietary for prostate
cancer [14]. Benign prostatic hyperplasia (BPH), prosta-
titis, infection and DRE increase serum PSA level [15].
In contrast, in 20–40% of patients with prostate cancer
that is confined to the prostate itself, the PSA level is
less than or equal to 4 ng/ml and does not increase.
Therefore, this diagnostic test lonely has a low screening
value [16–18]. Needle biopsies are also carried out in ad-
vanced stages of the cancer for microscopic examination
[19]. Screening tests can identify people who may have a
chance of developing the disease before detection and
any symptoms [20–23]. Experimental and clinical obser-
vations indicate that age, geographical area, ethnic differ-
ence, family history, obesity, androgens and various
genetic alterations have a role in the pathogenesis of
prostate cancer [24–28]. The genetic alterations involved
in tumorigenicity include Somatic copy number alter-
ations (SCNAS), structural rearrangement, point muta-
tions, single nucleotide polymorphisms (SNPs) and
miRNAs [20]. SNPs are important in genomic studies
because there is a significant association between them
and various biological traits. This genetic marker is re-
sponsible for over 90% of genetic variations that affect
the function of genes and cause the difference in the
susceptibility of individuals to cancer [29–31]. There are
numerous ways for efficient genomic studies, such as
multi-stage approach. In this method, a smaller number
of people can be used to detect subjects’ genotypes. In
the first stage, a complete set of SNPs is examined in a
limited number of individuals (according to the normal
distribution, individuals are selected from two extremes
to make the most difference) at liberal p-value. In the
next stages, the SNPs selected in the first phase are stud-
ied in larger population at more stringent P-value. Even-
tually, from the several candidate SNPs in the first
phase, only a small number of SNPs are in actual associ-
ation with the target trait [32, 33].
SNPs that were investigated in this study are rs2735839,
rs721048, rs4242382, rs16901979 and rs1447295.
rs4242382, rs16901979 and rs1447295 are located on
8q24 locus. The 8q24 is a susceptibility locus for a wide-
range of cancers [23]. This locus, commonly referred to as
the gene desert, is highly conserved and consists of three
regions (Region 1: 128.54–128.62Mb; region 2: 128.12–
128.28Mb; region 3: 128.47–128.54Mb) based on fine
mapping [34]. The nearest genes to this chromosomal re-
gion are MYC (telomeric end) and FAM84B (centromeric
end) [35]. The mechanism by which 8q24 can lead to
prostate cancer is still not well understood [23], but there
are assumptions that these variants can change the MYC
protein expression and affect the Wnt signaling pathway
[35]. rs4242382 is located at 230 Kb from MYC gene, and
along with rs16901979 are in 8q24 region 2 [23].
rs1447295 C >A is located about 263 kilobases from MYC
telomeric end in 8q24 region 1 [34–38]. rs2735839 G/A,
an intergenic polymorphism is located on chromosome
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19q13.33, at 600 base pairs downstream of the Kallikrein
– related peptidase 3 (KLK3) gene untranslatable region
[39–41]. The KLK3 gene encodes the prostate-specific
antigen, which is widely used in the screening of prostate
cancer [42]. rs721048 is located in the EHBP1 gene intron
at 2P15. This gene encodes Eps15 homology domain bind-
ing protein, which binds clathrin-dependent endocytosis
to the cytoskeleton [22].
The purpose of this study was to evaluate the associ-
ation of rs16901979, rs4242382, rs1447295, rs2735839
and rs721048 with prostate adenocarcinoma and clinical
information compared to BPH through multi-stage ap-
proach in Iranian population. The published results of
various studies in different population are sometimes
similar and in some cases different. To date, these poly-
morphisms have not been studied in Iranian popula-
tions. Associated polymorphisms with prostate cancer
can be a candidate biomarker for screening test.
Methods
Patients
In this case-control study, 103 men with prostate adeno-
carcinoma (case) and 100 age-matched men with BPH
(control) who referred to Shahid Hasheminejad Hospital
in Tehran. Iran, from January 2016 to June 2017 were
assessed. The sampling was carried out randomly. Diag-
nosis was made based on the PSA level, DRE, prostate
biopsy and physician confirmation so only prostate can-
cer patients with adenocarcinoma and BPH with no his-
tory of cancer were selected in this study. BPH was used
as a control because the biopsy showed that the person
did not have cancer. Selection of controls derived from
the same ethnic population as cases. Patients’ clinical
data included age at diagnosis, serum PSA level, prostate
volume, Gleason score, extraprostatic extension and
perineural invasion.
Written informed consent was obtained from all partici-
pants. This research and all methods were performed in
accordance with the ethical principles, the national norms,
standards, relevant guidelines and regulations for conduct-
ing Medical Research in Iran. The study has been ap-
proved by the research ethics committee of Kharazmi
University (Azizolah Habibi: Organic chemistry, Jafar
Jahan Panah: Physics, Mahdi Abbasi Sarmadi: Inter-
national law, Ali Akbar Imani: Clergy, Mahdi Akbarzadeh:
Biostatistics/Epidemiologist, Mahdi Tehranidoost: Bio-
medical Ethics, Fatemeh Javaheri: Sociology, Jafar Hasani:
Clinical Neuropsychology, Alireza Moradi: Clinical Psych-
ology and Zolfaghar Shaker: Communication Sciences)
(Approval ID: IR.KHU.REC.1398.002). Peripheral blood
samples were taken from patients before initiation of any
systemic treatment. The sample size was calculated
through the following formula: N = (Z1 – α /2)2 p (1-p) /
d2, Z1 – α /2 = 1.96, p = 0.72, d = 0.1, α = 0.05, N = 78.
According to this calculation, the minimum number of
people surveyed in this study was 78 patients, however,
more people were studied.
DNA extraction
Genomic DNA was extracted from peripheral blood lym-
phocytes using FavorPrep™ Blood Genomic DNA Extrac-
tion Mini Kit (Favorgen, Taiwan) instruction. The quality
and quantity of each DNA sample were verified using
1.5% agarose gel electrophoresis and NanoDrop™ spectro-
photometer respectively. The 260/280 ratio was 1.8.
SNP genotyping
Tetra-primer amplification refractory mutation system
PCR (T-ARMS-PCR) assay was used for SNP genotyping
of each participant. The primer design was done using
the Primer1 database and validated through the Primer-
BLAST-NCBI database. In this method, four primers in
a reaction are used for genotyping, which include two
non-specific outer primers and two allele-specific inner
primers. In order to enhance the specificity, mismatches
are introduced at the first and third position from the 3′
end of each of the two inner primers. Primer sequences,
the nucleotide determining the alleles of SNP (bold let-
ters) and primer products are shown in the Table 1.
Positive control (C+) is the product of two non-specific
outer primers. Negative control was also used to ensure
the absence of contamination in PCR.
MAF is minor allele frequency Which should be
greater than 0.01 to confirm SNP in that genetic region.
According to the 1000 genomes project, MAF has been
reported in rs721048 (A = 0.0944), rs4242382 (0.1873),
rs16901979 (A = 0.2119), rs1447295 (A = 0.1811) and
rs2735839 (A = 0.3245).
The PCR reactions were at a final volume of 25 μL and
contained 12.5 μL. TAQ DNA POLYMERASE 2X MASTER
MIX RED, 0.75 μL of each primer (10 pmol/μl), 2 μL DNA.
(50 NG/μl) and 7.5 μL. PCR-GRADE water. Initially using
Gradient PCR, the annealing temperature was selected for
rs721048, rs4242382, rs16901979 and rs1447295 polymor-
phisms, 60°c, 63°c, 57°c and 60°c respectively. The thermal
cycling condition of all polymorphisms includes: 1) PRE-
DENATURATION: 95°c. 5min. 1 cycle, 2) DENATUR-
ATION: 94°c. 30s. 32 cycles, 3) ANNEALING: 30s. 32 cycles.
4)EXTENSION: 72°c. 30s. 32 cycles and 5) FINAL EXTEN-
SION: 72°c. 3min. 1 cycle.
Statistical analysis
Chi-squared and Fisher’s exact test with p < 0.3 in the first
stage and p < 0.05 in the second stage were used to evaluate
genotype frequency, allelic frequency, Hardy-Weinberg equi-
librium (HWE), multiplicative and additive genetic models.
To investigate the SNPs associated with prostate cancer and
Gleason score, in the multiplicative and additive models and
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effect modification, Odds Ratios (OR) with 95% confidence
interval (95% CI) were calculated by logistic regression and
chi-squared test. Statistical significance was defined as p <
0.016 in order to address multiple-test issues by examining 3
SNPs in the second stage and applying a Bonferroni correc-
tion. Statistical analyses were performed using SPSS v.25.0.
Results
Patients characteristics (stage I)
In the first stage, 59 men were selected which included
30 men with prostate adenocarcinoma and 29 men with
BPH. The selection of subjects in the prostate adenocar-
cinoma group, which included the unhealthiest men, ac-
cording to Gleason score > 7, positive results of
perineural invasion and Extraprostatic extension was
done that individuals should have at least two of these
criteria. The choice of subjects in the BPH group, which
included the healthiest, was according to PSA < 4. In the
case and control groups, the age range was between 50–
84, 47–78 and the mean age was 71.77 ± 9.22, 62.66 ±
7.848.
Statistical analysis (stage I)
In the first stage, a complete set of SNPs with liberal P-
value (< 0.3) were examined to find meaningful polymor-
phisms. The genotype frequencies of these polymor-
phisms in each of the two groups are reported separately
in the Table 2. There was no significant difference be-
tween genotype distribution of rs721048 (p = 0.474) and
rs16901979 (p = 0.612) in case and control groups. With
the Chi-square test, prostatic cancer (P = 0.952, P =
0.612) and BPH (P = 0.72, P = 0.706) groups in relation
to rs721048 and rs16901979 respectively were under
HWE. Therefore, multiplicative and additive genetic
models were examined to evaluate the association of
these polymorphisms and the incidence of cancer. In
this study, GG (rs721048) and CC (rs16901979) are wild
genotypes, so they are considered as reference geno-
types. According to the Table 3 via Fisher’s exact test
and logistic regression, none of these two polymor-
phisms were associated with prostate cancer under the
multiplicative and additive genetic models. rs16901979
and rs721048 were not significant in any of the analysis
assay, so they were eliminated and in the next stage, only
polymorphisms rs4242382, rs2735839 and rs1447295
were evaluated.
Patients characteristics (stage II)
At this stage, genotyping of the three selected polymor-
phisms was performed in the rest of the participants
Table 1 Primer sequences and primer products



















































A (mutant) = 268 bp
G (wild) = 354 bp
A/G = 268/354 bp
C+ = 569 bp
G (wild) = 233 bp
A (mutant) = 355 bp
A/G = 355/233 bp
C+ = 532 bp
A (mutant) = 278 bp
C (wild) = 323 bp
A/C = 278/323 bp
C+ = 545 bp
C (wild) = 152 bp
A (mutant) = 228 bp
A/C = 228/152 bp
C+ = 327 bp
G (wild) = 179 bp
A (mutant) = 268 bp
A/G = 268/179 bp
C+ = 388 bp








AA 0 (0) 2 (6.9) 0.474
AG 7 (23.3) 5 (17.2)
GG 23 (76.7) 22 (75.9)
rs4242382 (A) Genotype
AA 1 (3.3) 0 (0) 0.236
AG 7 (23.3) 3 (10.3)
GG 22 (73.3) 26 (89.7)
rs16901979 (A) Genotype
AA 1 (3.3) 1 (3.4) 0.612
AC 1 (3.3) 3 (10.3)
CC 28 (93.3) 25 (86.2)
rs1447295 (A) Genotype
AA 0 (0) 0 (0) 0.171
AC 7 (25.9) 3 (10.3)
CC 20 (74.1) 26 (89.7)
rs2735839 (A) Genotype
AA 2 (6.7) 0 (0) 0.005
AG 6 (20) 0 (0)
GG 22 (73.3) 29 (100)
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(144 men). In the case (73 men) and control (71 men)
groups, the age range was between 48–86, 47–81 and
the mean age was 66.09 ± 7.8, 66.21 ± 7.9. All partici-
pants of the study (203 men) included 103 prostate
adenocarcinomas with age range of 48–86 and 100 BPH
with age range of 47–81. The mean age in the case
group was 67.75 ± 8.61 and 65.18 ± 8.24 in the control
group and totally in the 203 men was 66.48 ± 8.41. The
clinical and demographic information of the participants
are presented in Table 4.
Statistical analysis (stage II)
Since the statistical analysis of the first stage was per-
formed only for the selection of meaningful polymor-
phisms in order to examination in the second stage, the
statistical analysis of this stage included all participants
(203 men). First, in three polymorphisms (rs4242382,
rs1447295, rs2735839), the Hardy-Weinberg equilibrium
was studied in two groups by using Chi-square test.
There was no statistically significant difference between
the observed and expected genotype frequency in the
adenocarcinoma (rs4242382 [p = 1], rs1447295 [p =
0.854], rs2735839 [p = 0.655]) and BPH (rs4242382 [p =
1], rs1447295 [p = 1], rs2735839 [p = 1]) groups. The
genotype frequency of these polymorphisms is reported
in the Table 5.
The association of rs4242382 (P = 0.001, OR [95% CI] =
4.466 [1.791–11.136]), rs1447295 (P = 0.007, OR [95%
CI] = 3.432 [1.341–8.786]) and rs2735839 (P = 0.00, OR
[95% CI] =3.927 [2.085–7.397] with prostate adenocarcin-
oma was observed under the multiplicative genetic model.
In this study, GG (rs4242382, rs2735839) and CC
(rs1447295) are wild genotypes, so they are considered as
reference genotypes. According to the additive genetic
model, AG (rs4242382) is associated with prostate cancer
(OR = 95% CI) = 4.561 [1.769–11.758], P = 0.00) using GG
as a reference genotype. There was a significant difference
between genotype frequency AG+AA in the case
compared to control group (OR [95% CI] = 4.759 [1.853–
12.224], P = 0.00). AC (rs1447295) is associated with pros-
tate cancer (OR [95% CI] = 3.721 [1.418–9.767], P = 0.005)
using CC as a reference genotype. AG (rs2735839) is asso-
ciated with prostate cancer (OR = 95% CI) =5.038 [2.44–
10.38], P = 0.00) using GG as a reference genotype. There
was a significant difference between genotype frequency
AG+AA in the case compared to control group (OR
[95% CI] = 4.991 [2.475–10.065], P = 0.00). All of these as-
sociations remained significant after Bonferroni correction
(p < 0.016).
In Table 6, genotype and allelic frequency, the
OR[95%CI] (logistic regression) and P-value (Fisher’s
exact test) of risk allele compared to wild allele at three
categories of Gleason score were presented. According
to this table, there is a significant difference between the
frequency of allele A vs G in all three categories of Glea-
son score at rs42423820 and rs2735839. At rs1447295,
there is a significant difference between frequency of al-
lele A vs C only in the Gleason score ≥ 8. After Bonfer-
roni correction, rs4242382 did not associate with
Gleason Score = 7 and rs1447295 with any Gleason
Score categories.
Table 3 Multiplicative and additive genetic models
dbSNP Multiplicative model Additive model
rs721048 A vs G AA vs GG AG vs GG GG
OR 0.719 1.091 1.339 1 (Reference)
95%CI 0.249–2.078 0.967–1.231 0.369–4.855
P-Value 0.541 0.489 0.656
rs16901979 A vs C AA vs CC AC vs CC CC
OR 0.558 0.893 0.298 1 (Reference)
95%CI 0.127–2.449 0.053–15.036 0.029–3.048
P-Value 0.487 1.000 0.352






Age < 60 17 (16.5) 26 (26)
60–69 37 (35.9) 41 (41)
≥70 49 (47.6) 33 (33)
PSA (ng/ml) ≤4 13 (12.6) 19 (19)
4.1–10 47 (45.6) 56 (56)
> 10 43 (41.7) 25 (25)
Gleason score < 7 14 (13.6) –
7 47 (45.6) –
≥8 42 (40.8) –
Perineural invasion + 65 (63.1) –
– 38 (36.9) –
Extra prostatic extension + 18 (17.5) –
– 85 (82.5) –
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Using Fisher’s exact test, no significant difference was
found between the distribution of genotype at
rs4242382, rs1447295 and rs2735839 with the perineural
invasion and extraprostatic extension (Table 7).
Effect modification
In this study, age and PSA were investigated as an effect
modification. According to Table 8, Age and PSA were
categorized into 3 subgroups. The association of
rs4242382, rs2735839 and rs1447295 with prostate cancer
was investigated in each subgroup (df = 2). However, in
none of these polymorphisms, total OR was significantly
different with odds ratio of subgroup, so age and PSA are
not considered as effect modification in this study.
Discussion
In the present study, polymorphisms rs16901979, rs1447295
and rs4242382, rs2735839 and rs721048 were evaluated in
the prostate cancer compared to control group (BPH) in
Iranian population for the first time. In the first stage [43],
which included the unhealthiest and healthiest participants,
rs16901979 and rs721048 did not show any significant asso-
ciation with prostate adenocarcinoma. There was no signifi-
cant difference between the genotype frequency of





P-Value Multiplicative model Additive model
rs4242382 Genotype A vs G AA vs GG AG vs GG GG
AA 1 (1) 0 (0)
0.001
OR 4.466 3.56 4.561 1(Reference)
AG 23 (22.3) 6 (6) 95%CI 1.791–11.136 0.14–88.76 1.769–11.758
GG 79 (76.7) 94 (94) P-Value 0.001 0.438 0.001
rs1447295 Genotype A vs C AC vs CC CC
AA 0 (0) 0 (0)
0.005
OR 3.432 3.721 1 (Reference)
AC 19 (19.2) 6 (6) 95%CI 1.341–8.786 1.418–9.767
CC 80 (80.8) 94 (94) P-Value 0.007 0.005
rs2735839 Genotype A vs G AA vs GG AG vs GG GG
AA 3 (2.9) 1 (1)
0.00
OR 3.927 4.424 5.038 1 (Reference)
AG 41 (39.8) 12 (12) 95%CI 2.085–7.397 0.44–43.56 2.44–10.38
GG 59 (57.3) 87 (87) P-Value 0.00 0.307 0.00








A G OR (95%CI) P-Value
Control 0 (0) 6 (6) 94 (94) 6 (0.03) 194 (0.97) 1(reference) –
Gleason score < 7 0 (0) 5 (35.7) 9 (64.3) 5 (0.178) 23 (0.821) 7.029 (1.988–24.856) 0.005
7 0 (0) 8 (17) 39 (83) 8 (0.08) 86 (0.91) 3.008 (1.013–8.933) 0.039
≥8 1 (2.4) 10 (23.8) 31 (73.8) 12 (0.14) 72 (0.85) 5.389 (1.95–14.894) 0.00
rs2735839 AA AG GG A G OR (95%CI) P-Value
Control 1 (1) 12 (12) 87 (87) 14 (0.07) 186 (0.93) 1(reference) –
Gleason score < 7 0 (0) 7 (50) 7 (50) 7 (0.25) 21 (0.75) 4.429 (1.608–12.199) 0.007
7 1 (2.1) 15 (31.9) 31 (66) 17 (0.18) 77 (0.81) 2.933 (1.378–6.244) 0.004
≥8 2 (4.8) 19 (45.2) 21 (50) 23 (0.27) 61 (0.72) 5.009 (2.427–10.339) 0.00
rs1447295 AA AC CC A C OR (95%CI) P-Value
Control 0 (0) 6 (6) 94 (94) 6 (0.03) 194 (0.97) 1(reference) –
Gleason score < 7 0 (0) 3 (21.4) 11 (78.6) 3 (0.107) 25 (0.89) 3.88 (0.913–16.494) 0.084
7 0 (0) 8 (17) 39 (83) 8 (0.08) 86 (0.91) 3.008 (1–8.933) 0.073
≥8 0 (0) 8 (21) 30 (78.9) 8 (0.105) 68 (0.89) 3.804 (1.274–11.359) 0.026
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rs16901979 (P = 0.671) and rs721048 (P = 0.474) in both case
and control groups. According to the multiplicative and
additive genetic models, the association of these polymor-
phisms with prostate adenocarcinoma was not observed, so
rs16901979 and rs721048 were eliminated at first stage.
There was a significant difference between genotype distribu-
tion of rs4242382, rs1447295 and rs2735839 in both case
and control groups in the first stage (P = 0.236, 0.171, 0.005).
Therefore, these polymorphisms were chosen for the second
stage studies as candidate SNPs. According to all participants
(203 men), rs4242382 (AG Vs GG) (OR [95% CI] = 4.561
[1.769–11.758], P = 0.00), rs1447295 (AC Vs CC) (OR [95%
CI] = 3.721 [1.418–9.767], P = 0.005) and rs2735839 (AG Vs
GG) (OR [95% CI] = 5.038 [2.444–10.384], P = 0.0) were as-
sociated with cancer under additive genetic model. Also, ac-
cording to the multiplicative genetic model, the association
of these three polymorphisms, rs4242382 (A vs G) (OR [95%
CI] = 4.466 [1.791–11.136] P-Value = 0.001), rs1447295 (A vs
C) (OR [95% CI] = 3.432 [1.341–8.786] P-Value = 0.007) and
rs2735839 (A vs G) (OR [95% CI] = 3.927 [2.085–7.397] P-
Value = 0.00) with prostate adenocarcinoma was reported.
All of these associations remained significant after Bonferroni
correction (p < 0.016). There was a significant difference be-
tween the allelic frequency of A vs G (rs4242382, rs2735839)
at all three classes of Gleason score and A vs C (rs1447295)
at Gleason score ≥ 8 Which probably indicates the associ-
ation of this polymorphism (rs1447295) with the invasive
prostate cancer but after Bonferroni correction, rs4242382
did not associate with Gleason Score = 7 and rs1447295 with
any Gleason Score categories. No significant difference was
found between genotype frequency and clinical features such
as perineural invasion and extraprostatic extension.
Among genomic changes that are associated with the
development of prostate cancer, the variants in 8q24
chromosomal region are very important. In European
and American populations, several variants have been
identified in this locus for prostate cancer, but similar
studies have been conducted less in Asian populations
[23]. More than 11 Genome Wide Association Study
(GWAS) have identified strong association between the
8q24 chromosome and the risk of this cancer. Variants
of this locus can affect the regulation or transcription of
a causative gene outside this region. MYC (proto-onco-
gene) at the telomeric end is a strong candidate gene in
this field. The transcription factor encoded by c-MYC
regulates the expression of multiple genes responsible
for cell proliferation, cell differentiation and apoptosis
[35]. FAM84B (at the centromeric end) expression, in-
creases during prostate tumorigenesis and progression
[35, 37]. rs2735839 G/A is located at 600 base pairs
downstream of the KLK3 gene (PSA) 3′ untranslated re-
gion, which codes PSA [40, 41]. PSA (30-kDa) is a prote-
ase, which is released by the prostate gland epithelial
cells into seminal fluid and blood. PSA can cleave a
number of proteins, such as the insulin-like growth
factor binding protein (IGFBP2,3,5), Parathyroid
hormone-related protein (PTH-related protein), latent
TGF-β2, fibronectin and laminin (extracellular matrix
components) Whose destruction is the first step in
tumorigenesis, metastasis and development of prostate
cancer [44–46]. In prostate cancer, serum PSA level usu-
ally increases, which can induce mutations in P53 and
up-regulation of the B-cell lymphoma 2 protein that in-
hibits apoptosis in tumor cells [47]. rs721048 A/G is lo-
cated in the intron of EHBP1 gene. This gene encodes
Eps15 homology domain binding protein. Upregulation
of the NPF motif contained in EHBP1 causes degrad-
ation of the actin structure. However, the precise mech-
anism of EHBP1 in the onset and progression of
prostate cancer are still unknown [22].
The effect modification is seen when the association of
exposure and outcome varies according to a third factor,
Indeed, the exposure can have a different effect among
the different subgroups [48, 49]. We investigated
whether age and PSA were an effect modifier in
Table 7 Genotype distribution of polymorphisms and p-value in
mentioned clinical features
rs4242382 AA AG GG P-Value
Perineural invasion + 1 (1.5) 13 (20) 51 (78.5) 0.763
– 0 (0) 10 (26.13) 28 (73.7)
Extraprostatic extension + 1 (5.6) 4 (22.2) 13 (72.2) 0.27
– 0 (0) 19 (22.4) 66 (77.6)
rs1447295 AA AC CC P-Value
Perineural invasion + 0 (0) 11 (17.7) 51 (82.3) 0.635
– 0 (0) 8 (21.6) 29 (78.4)
Extraprostatic extension + 0 (0) 4 (23.5) 13 (76.5) 0.735
– 0 (0) 15 (18.3) 67 (81.7)
rs2735839 AA AG GG P-Value
Perineural invasion + 3 (4.6) 25 (38.5) 37 (56.9) 0.600
– 0 (0) 16 (42.1) 22 (57.9)
Extraprostatic extension + 1 (5.6) 6 (33.3) 11 (61.1) 0.527
– 2 (2.4) 35 (41.2) 48 (56.5)
Table 8 Effect modification
Age PSA
dbSNP < 60 60–69 ≥70 Total ≤4 4.1–10 > 10 Total
rs4242382 OR 2.41 6.98 4.04 4.46 1.8 9.29 4.66 4.46
X2 0.756 1.84
rs2735839 OR 15.69 4.24 2.22 3.92 – 5.73 1.62 3.92
X2 3.303 4.68
rs1447295 OR 0.86 3.76 6.72 3.43 4.82 3.08 2.57 3.43
X2 1.848 0.184
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association between exposure (rs4242382, rs2735839 and
rs1447295) and outcome (prostate cancer), but the effect
of rs4242382 (X2 = 0.756, X2 = 1.84), rs2735839 (X2 =
3.303, X2 = 4.68) and rs1447295 (X2 = 1.848, X2 = 0.184)
on prostate cancer was not modified by age and PSA re-
spectively. Therefore, exposure effect is homogeneous
between different ages and serum PSA level categories.
8q24 was initially identified by genome-wide linkage
study in the Icelandic families’ genome. Follow up these
subjects, displayed that the microsatellite DG8S737 (re-
peat of the two nucleotides AC) and rs1447295 had the
highest association with the risk of prostate cancer [50].
During a cohort study by Suuriniemi et al., rs1447295
had strong association with prostate cancer in 597 pros-
tate cancer patients and 548 European-American con-
trols [51] which was similar to the results of this study.
The results of this study for rs4242382 follow the Zheng
et al, studies which observed 1.3 to 1.9 times Increased
the risk of prostate cancer among European men with
either one or both rs4242382 risk alleles (A) (OR = 2.90;
95% CIs = 1.02–8.25 and OR = 2.90; 95% CIs = 1.02–
8.25) [52]. The effect of rs16901979 has been reported in
African-American population more than the Asian eth-
nic [23]. During a study on African ethnic related to
rs16901979, genotype AA and allele A were reported
with an increased risk of prostate cancer (OR = 1.84
[95%CI] = 1.26–2.69, P = 0.002 and OR = 1.36, 95% CI =
1.13–1.64, P = 0.001) as well as association of AC + AA
with Gleason score ≥ 7 (invasive prostate cancer) [53, 54]
which is contrary to the present study due to racial dif-
ferences. In a study by Cheng-Xiao Zhao et al., The re-
sults indicate that 8q24 rs4242382-A may be related to
the increased sensitivity to prostate cancer in Asian,
Caucasian, and African American populations. There-
fore, this polymorphism can be a multi-ethnic marker
[23]. During a meta-analysis, a total of 20,239 cases and
20,439 controls were studied for rs1447295 C > A and
1850 cases and 2090 controls for rs16901979 C > A.
rs1447295 was associated with the risk of prostate can-
cer in the Caucasian and Asian, but not African-
American. The effect of rs16901979 was high among
African-American more than the Asian [34].
In the first GWAS by Eles and colleagues, rs2735839
was identified as a risk factor for prostate cancer [55]
Which showed a stronger association with the PSA level
than previous polymorphisms [56]. Pomerantz et al.,
were found that rs2735839 (A) has been related to the
mortality in prostate cancer [57]. However, during a
meta-analysis between three KLK3 polymorphisms
(2018), no association was found about rs2735839 and
prostate cancer [58].
rs721048 (A) was first recognized by the GWA studies
in the Caucasian population as a risk factor for prostate
cancer. Through a meta-analysis, which included 48,135
cases and 10,254 controls, Xiang Ao et al., showed
strong association of this polymorphism with prostate
cancer (OR = 1.14, 95% CI = 1.11–1.17, P = 0.000) [22].
Unlike the Icelandic population, this polymorphism is
not associated with cancer in the Netherland, Spain and
Sweden population [43] as well as present study.
Conclusions
The results of this study indicate that polymorphisms
rs2735839, rs4242382 and rs1447295 are associated with
prostate cancer predisposition in Iranian population there-
fore, they may be considered as a biomarker for prostate
cancer. Exposure effect is homogeneous between different
ages and serum PSA level categories. Association of allele
A (rs4242382, rs2735839) with all three Gleason score cat-
egories and rs1447295 (A) only at Gleason score ≥ 8, was
observed. In future studies, it is suggested that these con-
firmed polymorphisms be examined in a larger population
and separately in each of the Iranian ethnic.
Research limitations
 Generally, markers should be validated by testing
their effectiveness in determining the target
phenotype in independent population and different
genetic backgrounds, which is referred to as marker
validation. In the present study, the association was
studied totally in Iranian population. Therefore, each
of these polymorphic markers should be investigated
separately in each Iranian race.
 Due to the limited population of the present study,
the association of these polymorphisms in a larger
population should be investigated for a more
accurate conclusion.
 Performing NGS on patient samples can provide
more comprehensive results regarding this cancer in
the Iranian population.
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